2-(4-Chlorobenzylideneamino)-5-Thioxoisothiazolidin-3-One Modified Pomegranate Juice for Anticancer Activity Applications | ||||
| Egyptian Journal of Chemistry | ||||
| Volume 67, Issue 13, December 2024, Page 341-347 PDF (509.21 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ejchem.2024.257288.9037 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
tayseer zidan  1; nermeen Ahmed2
| ||||
| 1Department of Polymers and Pigments, National Research Centre, 33 El Buhouth St., Dokki, Giza 12622, Egypt | ||||
| 2Radiation Biology Department, National Center for Radiation Research and Technology, Egyptian Atomic Energy Authority, Cairo, Egypt. | ||||
| Abstract | ||||
| Pomegranate juice has therapeutic effect observed through in vitro and in vivo studies. It can be used as antiviral, antibacterial, antidiabetic and anticarcinogenic material. This work includes in vitro studies for modified pomegranate as anticancer for liver and breast cancer. N-aminorhodanine is reacted with p-chlorobenzaldehyde to form 2-(4-chlorobenzylideneamino)-5-thioxoisothiazolidin-3-one (CBAT). CBAT was characterized with FTIR and 1HNMR. Pomegranate juice is then modified with CBAT. CBAT is reacted with phenolic –OH groups of pomegranate juice to make modification. The modified pomegranate was characterized using FTIR and 1HNMR spectroscopy. It was examined against both human hepatoma HepG2 cells and breast cancer cells MCF7 through in vitro studies. It was found that modified pomegranate has good synergistic inhibitory and pro apoptotic effects on human hepatoma HepG2 cells and breast cancer cell MCF7. Modified pomegranate has stronger effect on HepG2 cells than on MCF7 cells. | ||||
| Keywords | ||||
| Pomegranate; N-Aminorhodanine; Hepatoma HepG2 cells; Breast cancer cells MCF7; FTIR; 1HNMR | ||||
|
Statistics Article View: 69 PDF Download: 112 |
||||
